Barrett J. Tenbarge

Washington, D.C.
  • 555 Eleventh Street, NW
  • Suite 1000
  • Washington, D.C. 20004-1304
  • USA
 
 

Barrett Tenbarge is an associate in the Washington, D.C. office of Latham & Watkins.

Mr. Tenbarge’s practice focuses on healthcare and Food & Drug Administration (FDA) regulatory issues for healthcare providers and pharmaceutical, medical device, biotechnology, food, and other life sciences companies. Mr. Tenbarge has experience advising on transactional, litigation, regulatory, legislative, and antitrust matters in the healthcare and life sciences industries. Mr. Tenbarge also maintains a robust pro bono practice.

Mr. Tenbarge has experience advising clients in all stages of the biotechnology and food product lifecycle, including pre-market regulatory communications and submissions, clinical trials and related requirements, contract matters, promotion and labeling, post-market inspections and recalls, administrative interactions and appeals, investigations, reimbursement strategy, and antitrust merger control and enforcement. He also advises financial institutions, healthcare providers and suppliers, and life sciences companies on healthcare and FDA regulatory matters in connection with mergers and acquisitions, equity offerings, financings, and other transactions. Mr. Tenbarge also counsels clients concerning compliance and regulatory matters arising under the US Consumer Product Safety Commission (CPSC).

Mr. Tenbarge earned his JD from Vanderbilt University School of Law, where he served as an articles editor on the Vanderbilt Law Review and Environmental Law and Policy Annual Review. While in law school, Mr. Tenbarge worked as a law clerk in the Office of the Solicitor General of the State of Tennessee.

Mr. Tenbarge earned his BS with majors in Public Policy Analysis, Entrepreneurship & Corporate Innovation and Management from the Kelley School of Business at Indiana University where he was a Herman B Wells Scholar.

Thought Leadership
  • “ACA Repeal and Replace Bill Merits Attention from Industry Stakeholders,” Latham & Watkins Client Alert (May 2017)
  • “FDA Issues Draft Guidance on Biosimilar Interchangeability,” Latham & Watkins Client Alert (January 2017)
  • President Obama Signs the 21st Century Cures Act Into Law,” Latham & Watkins Client Alert (December 2016)
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.